Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Imidazopyridine acyl-KAGDV as well as synthesis, antithrombotic activity and application thereof

A technology of imidazopyridine and formyl, which is applied in the application field of antithrombotic drugs, and can solve problems such as unsatisfactory antithrombotic activity

Inactive Publication Date: 2017-08-11
CAPITAL UNIVERSITY OF MEDICAL SCIENCES
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, the inventors were not satisfied with the antithrombotic activity of this series of compounds

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Imidazopyridine acyl-KAGDV as well as synthesis, antithrombotic activity and application thereof
  • Imidazopyridine acyl-KAGDV as well as synthesis, antithrombotic activity and application thereof
  • Imidazopyridine acyl-KAGDV as well as synthesis, antithrombotic activity and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1 Preparation of 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-carboxylic acid (1)

[0027] Slowly add 0.8mL H 2 SO 4 , to dissolve completely. To this solution was added 6 mL of 40% aqueous formaldehyde. The ice bath was removed, and the reaction was carried out at 60° C. for 8 h. TLC (ethyl acetate: water: glacial acetic acid = 4:1:1) monitored the disappearance of the starting point. The reaction solution was cooled to room temperature, and the pH was adjusted to 6 with concentrated ammonia water in an ice bath, and a large amount of colorless solids were precipitated. filter. The filter residue was washed with water and acetone to afford 4.52 g (84%) of the title compound. ESI-MS(m / e): 168[M+H] + .

Embodiment 2

[0028] Example 2 Preparation of 3,5-di-Boc-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-carboxylic acid (2)

[0029] Add 40mL of 1,4 - 14.3 g (65.7 mmol) dissolved in dioxane (Boc) 2 O, adjust the pH to 8-9 with 4N NaOH solution, react at room temperature for 24 h, and monitor the disappearance of the raw material point by TLC (dichloromethane:methanol=15:1). The reaction solution was saturated KHSO 4 Adjust the pH of the solution to 7, evaporate 1,4-dioxane under reduced pressure, and then use saturated KHSO 4 The solution was adjusted to pH 2. It was extracted three times with ethyl acetate, and the ester layer was washed three times with saturated NaCl. Dry with anhydrous sodium sulfate for 30min and filter. The filtrate was evaporated to dryness under reduced pressure. Add a small amount of ethyl acetate to just dissolve it and let it stand. A solid precipitated and was filtered. Yield 1.2 g (11%) of the title compound as a colorless solid. ESI-MS(m / e): 368[M+H]...

Embodiment 3

[0030] Example 3 Preparation of 3,5-di-Boc-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-formyl-Lys(Boc)-OBzl(3)

[0031] 367 mg (1 mmol) of 3,5-di-Boc-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6 ​​was dissolved in 20 mL of dry tetrahydrofuran (THF) under ice bath - Carboxylic acid dissolves. Add 142mg (1.05mmol) HOBt and 258mg (1.25mmol) DCC, stir and activate for 30min. Dissolve 558 mg (1.1 mmol) Tos·Lys(Boc)-OBzl in 10 mL of dry THF, adjust the pH to 8 with NMM, add the solution dropwise to the reaction solution, and finally adjust the pH of the reaction solution to 8 with NMM. After reacting at room temperature for 5 h, TLC (petroleum ether: acetone = 3:1) showed that the starting material disappeared. Dicyclohexylurea (DCU) was removed by filtration, the reaction solution was evaporated to dryness under reduced pressure, and the residue was dissolved in ethyl acetate, followed by saturated NaHCO 3 solution, saturated NaCl solution, 5% KHSO 4 solution, saturated Na...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses 4,5,6,7-tetrahydro-3H-imidazo[4,5-c] pyridine-6-formyl-Lys-Ala-Gly-Asp-Val shown in a formula in the specification, a preparation method and antithrombotic activity of the compound and an application of the compound in preparation of antithrombotic drugs.

Description

[0001] field of invention [0002] The present invention relates to 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-formyl-Lys-Ala-Gly-Asp-Val, to its preparation method, to its antithrombotic activity, and thus the present invention relates to its use as an antithrombotic drug. The invention belongs to the field of biomedicine. Background technique [0003] Coronary heart disease, stroke, and vasculitis are very common cardiovascular and cerebrovascular diseases. With the continuous improvement of people's living standards, the incidence of cardiovascular and cerebrovascular diseases is increasing year by year. Risk factors for cardiovascular and cerebrovascular diseases are prevalent, and the prevalence of cardiovascular and cerebrovascular diseases in my country continues to rise. According to statistics, 1 out of every 5 adults suffers from cardiovascular disease. Thrombosis is an important cause of cardiovascular and cerebrovascular diseases. Prevention of thrombosis ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/06C07K1/02A61K38/08A61P7/02
Inventor 赵明彭师奇吴建辉王玉记张凇
Owner CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Features
  • Generate Ideas
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com